Drug intelligence / Profile preview

probiotics + metronidazole

Development stage: Unknown
Lead developer: Xinyi Pharmaceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Vaginal, Intravenous, Rectal

Overview

This is a combination therapy consisting of probiotics (commonly lactobacillus species such as Lactobacillus acidophilus or bifidobacterium infantis) and the antibiotic metronidazole. Metronidazole is a nitroimidazole-class small molecule antibiotic with both antibacterial and antiprotozoal activity, primarily used to treat anaerobic bacterial infections and certain protozoal diseases. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host by restoring or maintaining healthy microbiota balance. The rationale for combining these agents is to enhance treatment efficacy—particularly in conditions like bacterial vaginosis—by eradicating pathogenic bacteria with metronidazole while simultaneously replenishing beneficial flora with probiotics. Clinical studies suggest this combination may improve cure rates and reduce recurrence compared to metronidazole alone[2][4]. However, some studies report similar recurrence rates between combination therapy and monotherapy[6][9].

Targets

Neuraminidase

Beyond the preview

Go deeper on probiotics + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on probiotics + metronidazole.

Explore the full profile